Cited by 2,409Glioma Diagnosis and TreatmentMedical Imaging Techniques and ApplicationsOvarian cancer diagnosis and treatment

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Response criteria for phase II studies of supratentorial malignant glioma.

Macdonald, D R, Cascino, T L, Schold, S C, Cairncross, J G·1990·Journal of Clinical Oncology

DOI 10.1200/jco.1990.8.7.1277

Open this paper in CoChat — free account

Abstract

We suggest "new" response criteria for phase II studies of supratentorial malignant glioma and favor rigorous criteria similar to those in medical oncology, with important modifications. Four response categories are proposed: complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD). Response in this scheme is based on major changes in tumor size on the enhanced computed tomographic (CT) or magnetic resonance imaging (MRI) scan. Scan changes are interpreted in light of steroid use and neurologic findings. We advocate careful patient selection, emphasize pitfalls in the assessment of response, and suggest guidelines to minimize misinterpretations of response.

Integrity signals

Registry

Crossref · 10.1200/jco.1990.8.7.1277

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Successful chemotherapy for recurrent malignant oligodendroglioma
Cairncross, J. G., & Macdonald, D. R. (1988) · Annals of Neurology · doi:10.1002/ana.410230408 · Cited by 345
Self-citation
Criteria for evaluating patients undergoing chemotherapy for malignant brain tumors
Levin, V. A., Crafts, D. C., Norman, D. M., Hoffer, P. B., Spire, J., & Wilson, C. B. (1977) · Journal of neurosurgery · doi:10.3171/jns.1977.47.3.0329 · Cited by 199
Residual abdominal masses in aggressive non-Hodgkin's lymphoma after combination chemotherapy: significance and management.
Surbone, A., Longo, D. L., Vt, D., Ihde, D. C., Duffey, P. L., Jaffe, E. S., Solomon, D., HUBBARD, S. M., & Young, R. C. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.12.1832 · Cited by 178
Influence of measurement error on assessment of response to anticancer chemotherapy: proposal for new criteria of tumor response.
Warr, D. G., McKinney, S., & Tannock, I. F. (1984) · Journal of Clinical Oncology · doi:10.1200/jco.1984.2.9.1040 · Cited by 151
Absence of contrast enhancement on CT brain scans of patients with supratentorial malignant gliomas
Chamberlain, M. C., Murovic, J. A., & Levin, V. A. (1988) · Neurology · doi:10.1212/wnl.38.9.1371 · Cited by 149
Steroid‐induced CT changes in patients with recurrent malignant glioma
Cairncross, J. G., Macdonald, D. R., Pexman, J. H. W., & Ives, F. J. (1988) · Neurology · doi:10.1212/wnl.38.5.724 · Cited by 100
Self-citation
Computerized tomography in the prognosis of malignant cerebral gliomas
Murovic, J. A., Turowski, K., Wilson, C. B., Hoshino, T., & Levin, V. A. (1986) · Journal of neurosurgery · doi:10.3171/jns.1986.65.6.0799 · Cited by 42
Criteria and definitions for response and relapse in children with brain tumors
Zeltzer, P. M., Friedman, H. S., Norris, D. G., & Ragab, A. H. (1985) · Cancer · doi:10.1002/1097-0142(19851001)56:7+ · Cited by 35
Post-Surgical Contrast Enhancement Mimicking Residual Brain Tumour
Cairncross, J. G., Pexman, J. H. W., & Rathbone, M. P. (1985) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100046643 · Cited by 33
Self-citation
The accuracy of volumetric measurement of high-grade gliomas
Chisholm, R. A., Stenning, S. P., & Hawkins, T. D. (1989) · Clinical Radiology · doi:10.1016/s0009-9260(89)80007-8 · Cited by 32

Flagged first, then by citations

Show all 11 references

Sorted by citations

Items 801–900 of 1,001

Chemoradiotherapy of Newly Diagnosed Glioblastoma With Intensified Temozolomide
Weiler, M., Hartmann, C. J., Wiewrodt, D., Herrlinger, U., Gorlia, T., Bähr, O., Meyermann, R., Bamberg, M., Tatagiba, M. S., von Deimling, A., et al. (2009) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.05.031 · Cited by 57
Temozolomide as salvage treatment for recurrent intracranial ependymomas of the adult: a retrospective study
Rudà, R., Bosa, C., Magistrello, M., Franchino, F., Pellerino, A., Fiano, V., Trevisan, M., Cassoni, P., & Soffietti, R. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov167 · Cited by 57
Phase II trial of an AKT inhibitor (perifosine) for recurrent glioblastoma
Kaley, T. J., Panageas, K. S., Mellinghoff, I. K., Nolan, C. P., Gavrilovic, I. T., DeAngelis, L. M., Abrey, L. E., Holland, E. C., & Lassman, A. B. (2019) · Journal of Neuro-Oncology · doi:10.1007/s11060-019-03243-7 · Cited by 57
Treatment of Malignant Gliomas in the Elderly
Pierga, J., Hoang‐Xuan, K., Feuvret, L., Simon, J.-M., Cornu, P., Baillet, F., Mazeron, J., & Delattre, J. (1999) · Journal of Neuro-Oncology · doi:10.1023/a:1006262918694 · Cited by 57
Vessel calibre—a potential MRI biomarker of tumour response in clinical trials
Emblem, K. E., Farrar, C. T., Gerstner, E. R., Batchelor, T. T., Borra, R., Rosen, B. R., Sorensen, A. G., & Jain, R. K. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.126 · Cited by 58
Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy
Quinn, J. A., Jiang, X. “., Reardon, D. A., Desjardins, A., Vredenburgh, J. J., Friedman, A. H., Sampson, J. H., McLendon, R. E., Herndon, J. E., & Friedman, H. S. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-9937-x · Cited by 56
Observational, retrospective study of the effectiveness of 5-aminolevulinic acid in malignant glioma surgery in Spain (The VISIONA study)
Valle, R. D., Slof, J., Galván, J., Arza, C., Romariz, C., & Vidal, C. (2014) · Neurología (English Edition) · doi:10.1016/j.nrleng.2013.05.004 · Cited by 57
A phase 2 trial of verubulin for recurrent glioblastoma: a prospective study by the brain tumor investigational consortium (BTIC)
Chamberlain, M. C., Grimm, S. A., Phuphanich, S., Recht, L. D., Zhu, J. Z. J., Kim, L., Rosenfeld, S., & Fadul, C. E. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-014-1437-y · Cited by 58
Phase 2 trial design in neuro-oncology revisited: a report from the RANO group
Galanis, E., Wu, W., Cloughesy, T. F., Lamborn, K. R., Mann, B., Wen, P. Y., Reardon, D. A., Wick, W., Macdonald, D., Armstrong, T. S., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70406-5 · Cited by 56
Self-citation
A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas
Raizer, J. J., Abrey, L. E., Lassman, A. B., Chang, S., Lamborn, K. R., Kuhn, J. G., Yung, W. K. A., Gilbert, M. R., Aldape, K., Wen, P. Y., et al. (2009) · Neuro-Oncology · doi:10.1093/neuonc/nop017 · Cited by 56
Efficacy of vinblastine in central nervous system Langerhans cell histiocytosis: a nationwide retrospective study
Tin, S. N. W., Martin-Duverneuil, N., Idbaïh, A., Garel, C., Ribeiro, M. J., Landman‐Parker, J., Defachelles, A. S., Lambilliotte, A., Barkaoui, M., Münzer, M., et al. (2011) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-6-83 · Cited by 56
Cediranib: profile of a novel anti-angiogenic agent in patients with glioblastoma
Dietrich, J., Wang, D., & Batchelor, T. T. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903183528 · Cited by 56
Extended-schedule dose-dense temozolomide in refractory gliomas
GENOM Cooperative Group, Berrocal, A., Segura, P. P., Gil, M., Balañá, C., López, J. G., Yayá, R., Rodríguez, J., Reynés, G., Gallego, O. S., et al. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-9980-7 · Cited by 56
Continuous low-dose temozolomide and celecoxib in recurrent glioblastoma
Stockhammer, F., Misch, M., Koch, A., Czabanka, M., Plotkin, M., Blechschmidt, C., Tuettenberg, J., & Vajkoczy, P. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0192-y · Cited by 56
Intra-arterial Cereport (RMP-7) and Carboplatin: A Dose Escalation Study for Recurrent Malignant Gliomas
Cloughesy, T. F., Black, K. L., Gobin, Y. P., Farahani, K., Nelson, G., Villablanca, P. J., Kabbinavar, F. F., Viñeula, F., & Wortel, C. H. (1999) · Neurosurgery · doi:10.1097/00006123-199902000-00015 · Cited by 56
Survival and prognostic factors of patients with unresectable glioblastoma multiforme
Fazeny-Dörner, B., Wenzel, C., Veitl, M., Piribauer, M., Rössler, K., Dieckmann, K., Ungersböck, K., & Marosi, C. (2003) · Anti-Cancer Drugs · doi:10.1097/00001813-200304000-00008 · Cited by 56
Defining Clinical Response Criteria and Early Response Criteria for Precision Oncology: Current State-of-the-Art and Future Perspectives
Subbiah, V., Chuang, H. H., Gambhire, D., & Kairemo, K. (2017) · Diagnostics · doi:10.3390/diagnostics7010010 · Cited by 55
Comparison of Stereotactic Brachytherapy (125Iodine Seeds) with Stereotactic Radiosurgery (LINAC) for the Treatment of Singular Cerebral Metastases
Ruge, M. I., Köcher, M., Maarouf, M., Hamisch, C., Treuer, H., Voges, J., & Sturm, V. (2010) · Strahlentherapie und Onkologie · doi:10.1007/s00066-010-2168-4 · Cited by 55
The Use of O-(2-18F-Fluoroethyl)-l-Tyrosine PET for Treatment Management of Bevacizumab and Irinotecan in Patients with Recurrent High-Grade Glioma: A Cost-Effectiveness Analysis
Heinzel, A., Müller, D., Langen, K., Blaum, M., Verburg, F. A., Mottaghy, F. M., & Galldiks, N. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.120089 · Cited by 57
Prognostic factors influencing clinical outcomes of glioblastoma multiforme.
Li, S., Qiu, X., Chen, B.-S., Zhang, W., Ren, H., Wang, Z., & Jiang, T. (2009) · PubMed · Cited by 55
Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology Working Group
Arvold, N. D., Armstrong, T. S., Warren, K. E., Chang, S. M., DeAngelis, L. M., Blakeley, J. O., Chamberlain, M. C., Dunbar, E. M., Loong, H. H.-F., Macdonald, D. R., et al. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy056 · Cited by 55
Self-citation
Safety, tolerability, and pharmacokinetics of anti-EGFRvIII antibody–drug conjugate AMG 595 in patients with recurrent malignant glioma expressing EGFRvIII
Rosenthal, M. A., Curry, R. C., Reardon, D. A., Rasmussen, E., Upreti, V. V., Damore, M. A., Henary, H. A., Hill, J. S., & Cloughesy, T. F. (2019) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-019-03879-2 · Cited by 55
Chronic oral VP-16 for recurrent medulloblastoma
Chamberlain, M. C., & Kormanik, P. A. (1997) · Pediatric Neurology · doi:10.1016/s0887-8994(97)00098-2 · Cited by 55
Response and progression in recurrent malignant glioma
Hess, K. R., Wong, E. T., Jaeckle, K. A., Kyritsis, A. P., Levin, V. A., Prados, M. D., & Yung, W. K. A. (1999) · Neuro-Oncology · doi:10.1093/neuonc/1.4.282 · Cited by 55
A role for preirradiation PCV chemotherapy for oligodendroglial brain tumors
Streffer, J. R., Schabet, M., BAMBERG, M., Grote, E. H., Meyermann, R., Voigt, K., DICHGANS, J., & Weller, M. (2000) · Journal of Neurology · doi:10.1007/s004150050587 · Cited by 55
Corticosteroid-use in primary and secondary brain tumour patients: a review
Ryan, R., Booth, S., & Price, S. J. (2011) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0713-3 · Cited by 54
Early Pseudoprogression following Chemoradiotherapy in Glioblastoma Patients: The Value of RANO Evaluation
Linhares, P., Carvalho, B., Figueiredo, R., Reis, R. M., & Vaz, R. M. (2013) · Journal of Oncology · doi:10.1155/2013/690585 · Cited by 54
Pseudoprogression in patients with malignant gliomas treated with concurrent temozolomide and radiotherapy: potential role of p53
Kang, H., Kim, C., Han, J. H., Choe, G. Y., Kim, J. H., Kim, J. H., & Kim, I. A. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0305-7 · Cited by 54
Current standards and new concepts in MRI and PET response assessment of antiangiogenic therapies in high-grade glioma patients
Hutterer, M., Hattingen, E., Palm, C., Proescholdt, M. A., & Hau, P. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou322 · Cited by 56
Use of bevacizumab in recurrent glioblastoma
Ghiaseddin, A. P., & Peters, K. B. (2015) · CNS Oncology · doi:10.2217/cns.15.8 · Cited by 54
Initial and cumulative recurrence patterns of glioblastoma after temozolomide-based chemoradiotherapy and salvage treatment: a retrospective cohort study in a single institution
Ogura, K., Mizowaki, T., Arakawa, Y., Ogura, M., Sakanaka, K., Miyamoto, S., & Hiraoka, M. (2013) · Radiation Oncology · doi:10.1186/1748-717x-8-97 · Cited by 54
Comparing available criteria for measuring brain metastasis response to immunotherapy
Qian, J. M., Mahajan, A. K., Yu, J. B., Tsiouris, A. J., Goldberg, S. B., Kluger, H. M., & Chiang, V. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2398-8 · Cited by 54
Neurotoxicity of combination chemotherapy with procarbazine, CCNU and vincristine (PCV) for recurrent glioma
Postma, T. J., van Groeningen, C. J., Witjes, R. J. G. M., Weerts, J. G. E., Kralendonk, J. H., & Heimans, J. J. (1998) · Journal of Neuro-Oncology · doi:10.1023/a:1005909318270 · Cited by 54
A Pilot Safety Study of Lenalidomide and Radiotherapy for Patients With Newly Diagnosed Glioblastoma Multiforme
Drappatz, J., Wong, E. T., Schiff, D., Kesari, S., Batchelor, T. T., Doherty, L. M., LaFrankie, D. C., Ramakrishna, N. R., Weiss, S. E., Smith, S. T., et al. (2008) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2008.03.046 · Cited by 54
Salvage chemotherapy with paclitaxel for recurrent oligodendrogliomas.
Chamberlain, M. C., & Kormanik, P. A. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.12.3427 · Cited by 54
Low-dose fractionated radiotherapy and concomitant chemotherapy in glioblastoma multiforme with poor prognosis: a feasibility study
Balducci, M., Chiesa, S., Diletto, B., D’Agostino, G. R., Mangiola, A., Manfrida, S., Mantini, G., Albanese, A., Fiorentino, A., Frascino, V., et al. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor173 · Cited by 53
Temozolomide for recurrent intracranial supratentorial platinum‐refractory ependymoma
Chamberlain, M. C., & Johnston, S. K. (2009) · Cancer · doi:10.1002/cncr.24524 · Cited by 53
Multimodal imaging of gliomas in the context of evolving cellular and molecular therapies
Keunen, O., Taxt, T., Grüner, R., Lund‐Johansen, M., Tonn, J., Pavlin, T., Bjerkvig, R., Niclou, S. P., & Thorsen, F. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.07.010 · Cited by 54
Independent prognostic value of pre-treatment 18-FDG-PET in high-grade gliomas
Colavolpe, C., Métellus, P., Mancini, J., Barrié, M., Bequet, C., Figarella-Branger, D. F., MUNDLER, O., Chinot, O. L., & Guedj, É. (2011) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0771-6 · Cited by 53
Leptomeningeal Metastases in High-Grade Adult Glioma: Development, Diagnosis, Management, and Outcomes in a Series of 34 Patients
Dardis, C., Milton, K., Ashby, L. S., & Shapiro, W. (2014) · Frontiers in Neurology · doi:10.3389/fneur.2014.00220 · Cited by 53
Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD)
Wen, P. Y., Cloughesy, T. F., Ellingson, B. M., Reardon, D. A., Fine, H. A., Abrey, L. E., Ballman, K. V., Bendszuz, M., Buckner, J. C., Chang, S. M., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou226 · Cited by 53
Differentiation between recurrent gliomas and radiation necrosis using arterial spin labeling perfusion imaging
Ye, J., Bhagat, S. K., Li, H., Luo, X., Wang, B., Liu, L., & Yang, G. (2016) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2016.3225 · Cited by 53
Treatment of unresectable glioblastoma multiforme.
Nieder, C., Grosu, A., Astner, S. T., & Molls, M. (2005) · PubMed · Cited by 53
Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma
Plotkin, S. R., Halpin, C. F., Blakeley, J. O., Slattery, W. H., Welling, D. B., Chang, S. M., Loeffler, J. S., Harris, G. J., Sorensen, A. G., McKenna, M. J., et al. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-9867-7 · Cited by 53
Retrospective study of prognostic factors in non-Hodgkin lymphoma secondarily involving the central nervous system
Jahnke, K., Thiel, E., Martus, P., Schwartz, S., & Korfel, A. (2005) · Annals of Hematology · doi:10.1007/s00277-005-1096-3 · Cited by 53
Radiotherapy for brain metastases: defining palliative response
Bezjak, A., Adam, J., Panzarella, T., Levin, W., Barton, R., Kirkbride, P., McLean, M., Mason, W. P., Wong, C. S., & Laperrière, N. (2001) · Radiotherapy and Oncology · doi:10.1016/s0167-8140(01)00426-1 · Cited by 53
2-Chlorodeoxyadenosine dose escalation in nonhematologic malignancies.
Saven, A., Kawasaki, H., Carrera, C. J., Waltz, T. A., Copeland, B. R., Zyroff, J., Kosty, M. P., Carson, D. A., Beutler, E., & Piro, L. D. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.4.671 · Cited by 53
Magnetic resonance spectroscopy as an early indicator of response to anti-angiogenic therapy in patients with recurrent glioblastoma: RTOG 0625/ACRIN 6677
Ratai, E., Zhang, Z., Snyder, B. S., Boxerman, J. L., Safriel, Y. I., McKinstry, R. C., Bokstein, F., Gilbert, M. R., Sorensen, A. G., & Barboriak, D. P. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not044 · Cited by 52
Response assessment of NovoTTF‐100A versus best physician's choice chemotherapy in recurrent glioblastoma
Wong, E. T., Lok, E., Swanson, K. D., Gautam, S., Engelhard, H. H., Lieberman, F. S., Taillibert, S., Ram, Z., & Villano, J. L. (2014) · Cancer Medicine · doi:10.1002/cam4.210 · Cited by 52
Glioblastoma Segmentation: Comparison of Three Different Software Packages
Fyllingen, E. H., Stensjøen, A. L., Berntsen, E. M., Solheim, O. S., & Reinertsen, I. (2016) · PLoS ONE · doi:10.1371/journal.pone.0164891 · Cited by 58
Pseudoprogression after glioma therapy: an update
Galldiks, N., Köcher, M., & Langen, K. (2017) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2017.1375405 · Cited by 52
The Emerging Role of Amino Acid PET in Neuro-Oncology
Najjar, A. M., Johnson, J. M., & Schellingerhout, D. (2018) · Bioengineering · doi:10.3390/bioengineering5040104 · Cited by 52
Early Treatment Response Assessment Using 18 F-FET PET Compared with Contrast-Enhanced MRI in Glioma Patients After Adjuvant Temozolomide Chemotherapy
Ceccon, G. S., Lohmann, P., Werner, J., Tscherpel, C., Dunkl, V., Stoffels, G., Rosen, J., Rapp, M., Sabel, M., Herrlinger, U., et al. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.254243 · Cited by 52
A Phase I Trial of Enzastaurin in Patients with Recurrent Gliomas
Kreisl, T. N., Kim, L., Moore, K., Duic, P., Kotliarova, S. E., Walling, J., Musib, L. C., Thornton, D., Albert, P. S., & Fine, H. A. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3071 · Cited by 52
Temozolomide for High Grade Glioma
Hart, M. G., Grant, R., Garside, R., Rogers, G., Somerville, M., & Stein, K. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007415 · Cited by 52
Bevacizumab and irinotecan in children with recurrent or refractory brain tumors: Toxicity and efficacy trends
Couec, M., André, N., Thébaud, E., Minckes, O., Rialland, X., Corradini, N., Aerts, I., Marec‐Bérard, P., Bourdeaut, F., Leblond, P., et al. (2012) · Pediatric Blood & Cancer · doi:10.1002/pbc.24066 · Cited by 51
Glioblastoma in elderly patients: Safety and efficacy of adjuvant radiotherapy with concomitant temozolomide
Fiorica, F., Berretta, M., Colosimo, C., Stefanelli, A., Ursino, S., Zanet, E., Palmucci, T., Maugeri, D., Malaguarnera, M., Palmucci, S., et al. (2009) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2009.06.011 · Cited by 51
Progress on Antiangiogenic Therapy for Patients with Malignant Glioma
Ahluwalia, M. S., & Gladson, C. L. (2010) · Journal of Oncology · doi:10.1155/2010/689018 · Cited by 55
Quantitative multiparametric MRI assessment of glioma response to radiotherapy in a rat model
Hong, X., Liu, L., Wang, M., Ding, K., Fan, Y., Ma, B. B. Y., Lal, B., Tyler, B., Mangraviti, A., Wang, S., et al. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not245 · Cited by 51
MRI patterns of T 1 enhancing radiation necrosis versus tumour recurrence in high‐grade gliomas
Reddy, K., Westerly, D., & Chen, C. (2013) · Journal of Medical Imaging and Radiation Oncology · doi:10.1111/j.1754-9485.2012.02472.x · Cited by 51
ACTC1 as an invasion and prognosis marker in glioma
Ohtaki, S., Wanibuchi, M., Kataoka-Sasaki, Y., Sasaki, M., Oka, S., Noshiro, S., Akiyama, Y., Mikami, T., Mikuni, N., Kocsis, J. D., et al. (2016) · Journal of neurosurgery · doi:10.3171/2016.1.jns152075 · Cited by 51
Comparison of 2D (RANO) and volumetric methods for assessment of recurrent glioblastoma treated with bevacizumab—a report from the BELOB trial
Gahrmann, R., van den Bent, M. J., van der Holt, B., Vernhout, R. M., Taal, W., Vos, M. J., de Groot, J. C., Beerepoot, L. V., Buter, J., Flach, Z. H., et al. (2017) · Neuro-Oncology · doi:10.1093/neuonc/now311 · Cited by 51
Biological basis and clinical study of glycogen synthase kinase- 3β-targeted therapy by drug repositioning for glioblastoma
Furuta, T., Sabit, H., Dong, Y. J., Miyashita, K., Kinoshita, M., Uchiyama, N., Hayashi, Y., Hayashi, Y., Minamoto, T., & Nakada, M. (2017) · Oncotarget · doi:10.18632/oncotarget.15206 · Cited by 51
A Bayesian adaptive randomized phase II multicenter trial of bevacizumab with or without vorinostat in adults with recurrent glioblastoma
Puduvalli, V. K., Wu, J., Yuan, Y., Armstrong, T. S., Vera, E., Xu, J., Xu, J., Giglio, P., Colman, H., Walbert, T., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa062 · Cited by 51
Phase II study of neoadjuvant 1, 3‐bis (2‐chloroethyl)‐1‐nitrosourea and temozolomide for newly diagnosed anaplastic glioma
Chang, S. M., Prados, M. D., Yung, W. K. A., Fine, H. A., Junck, L., Greenberg, H. S., Robins, H. I., Mehta, M. P., Fink, K., Jaeckle, K. A., et al. (2004) · Cancer · doi:10.1002/cncr.20157 · Cited by 51
The role of advanced MR imaging in understanding brain tumour pathology
Price, S. J. (2007) · British Journal of Neurosurgery · doi:10.1080/02688690701700935 · Cited by 51
Short-echo three-dimensional H-1 MR spectroscopic imaging of patients with glioma at 7 tesla for characterization of differences in metabolite levels
Li, Y., Larson, P. E. Z., Chen, A. P., Lupo, J., Ozhinsky, E., Kelley, D. A. C., Chang, S. M., & Nelson, S. J. (2014) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.24672 · Cited by 50
Tumour progression or pseudoprogression? A review of post-treatment radiological appearances of glioblastoma
Abdulla, S., Saada, J., Johnson, G., Jefferies, S., & Ajithkumar, T. (2015) · Clinical Radiology · doi:10.1016/j.crad.2015.06.096 · Cited by 50
Stereotactic LINAC radiosurgery for incompletely resected or recurrent atypical and anaplastic meningiomas
El-Khatib, M., Majdoub, F. E., Hoevels, M., Köcher, M., Müller, R., Steiger, H., Sturm, V., & Maarouf, M. (2011) · Acta Neurochirurgica · doi:10.1007/s00701-011-1073-7 · Cited by 50
Phase I study of arsenic trioxide and temozolomide in combination with radiation therapy in patients with malignant gliomas
Grimm, S. A., Marymont, M. H., Chandler, J. P., Muro, K., Newman, S. B., Levy, R. M., Jovanovic, B., McCarthy, K., & Raizer, J. J. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-012-0957-6 · Cited by 50
Inhibiting kinases in malignant gliomas
Chi, A. S., & Wen, P. Y. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.4.473 · Cited by 51
Predominant influence of MGMT methylation in non-resectable glioblastoma after radiotherapy plus temozolomide
Thon, N., Eigenbrod, S., Grasbon-Frodl, E. M., Lutz, J., Kreth, S., Pöpperl, G., Belka, C., Kretzschmar, H. A., Tonn, J.-C., & Kreth, F.-W. (2010) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2010.214593 · Cited by 50
Differentiation of local tumor recurrence from radiation-induced changes after stereotactic radiosurgery for treatment of brain metastasis: case report and review of the literature
Kickingereder, P., Dorn, F., Blau, T., Schmidt, M. C., Köcher, M., Galldiks, N., & Ruge, M. I. (2013) · Radiation Oncology · doi:10.1186/1748-717x-8-52 · Cited by 50
Clinical Relevance of Steroid Use in Neuro-Oncology
Ly, I., & Wen, P. Y. (2017) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-017-0713-6 · Cited by 51
Phase I/II study of bevacizumab with BKM120, an oral PI3K inhibitor, in patients with refractory solid tumors (phase I) and relapsed/refractory glioblastoma (phase II)
Hainsworth, J. D., Becker, K. P., Mekhail, T. M., Chowdhary, S. A., Eakle, J. F., Wright, D. D., Langdon, R. M., Yost, K. J., Padula, G. D. A., West-Osterfield, K., et al. (2019) · Journal of Neuro-Oncology · doi:10.1007/s11060-019-03227-7 · Cited by 52
Defining pseudoprogression in glioblastoma multiforme
Mieghem, E. V., Woźniak, A., Geussens, Y., Menten, J. J., Vleeschouwer, S. D., Calenbergh, F. V., Sciot, R., Gool, S. V., Bechter, O. E., Demaerel, P., et al. (2013) · European Journal of Neurology · doi:10.1111/ene.12192 · Cited by 50
Recurrent spinal cord glioblastoma: salvage therapy with bevacizumab
Chamberlain, M. C., & Johnston, S. K. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0330-6 · Cited by 50
A phase II study of concurrent temozolomide and cis-retinoic acid with radiation for adult patients with newly diagnosed supratentorial glioblastoma
Butowski, N. A., Prados, M. D., Lamborn, K. R., Larson, D. A., Sneed, P. K., Wara, W. M., Malec, M. K., Rabbitt, J. E., Page, M., & Chang, S. M. (2005) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2004.08.023 · Cited by 50
Two phase II trials of temozolomide with interferon-α2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme
Groves, M. D., Puduvalli, V. K., GILBERT, M. R., Levin, V. A., Conrad, C. A., Liu, V., Hunter, K., Meyers, C., Hess, K. R., & Yung, W. K. A. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605189 · Cited by 50
Pineal Parenchymal Tumors
Maarouf, M., Majdoub, F. E., Bührle, C., Voges, J., Lehrke, R., Köcher, M., Hunsche, S., Treuer, H., & Sturm, V. (2010) · Strahlentherapie und Onkologie · doi:10.1007/s00066-010-2096-3 · Cited by 49
Epilepsy and insular Grade II gliomas: an interdisciplinary point of view from a retrospective monocentric series of 46 cases
Taillandier, L., & Duffau, H. (2009) · Neurosurgical FOCUS · doi:10.3171/2009.6.focus09102 · Cited by 49
Change in Pattern of Relapse After Antiangiogenic Therapy in High-Grade Glioma
Narayana, A., Kunnakkat, S., Medabalmi, P., Golfinos, J. G., Parker, E. C., Knopp, E. A., Zagzag, D., Eagan, P., Gruber, D., & Gruber, M. L. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.10.038 · Cited by 49
Vaccination with dendritic cells loaded with allogeneic brain tumor cells for recurrent malignant brain tumors induces a CD4+IL17+ response
Olin, M. R., Low, W. C., McKenna, D. H., Haines, S. J., Dahlheimer, T., Nascene, D. R., Gustafson, M. P., Dietz, A. B., Clark, H. B., Chen, W., et al. (2014) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-2-4 · Cited by 49
Bevacizumab for the treatment of high-grade glioma: an update after Phase III trials
Khasraw, M., Ameratunga, M., & Grommes, C. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.898060 · Cited by 49
Clinical Applications of Choline PET/CT in Brain Tumors
Giovannini, E., Lazzeri, P., Milano, A., Gaeta, M. C., & Ciarmiello, A. (2014) · Current Pharmaceutical Design · doi:10.2174/1381612820666140915120742 · Cited by 49
18F-Fluoroethylcholine (18F-Cho) PET/MRI Functional Parameters in Pediatric Astrocytic Brain Tumors
Fraioli, F., Shankar, A., Hargrave, D. R., Hyare, H., Gaze, M. N., Groves, A. M., Alongi, P., Stoneham, S. J., Michopoulou, S. K., Syed, R., et al. (2014) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000000556 · Cited by 49
Response Patterns of Recurrent Glioblastomas Treated With Tumor-Treating Fields
Vymazal, J., & Wong, E. T. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.09.009 · Cited by 49
Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide
Polley, M.-Y. C., Lamborn, K. R., Chang, S. M., Butowski, N. A., Clarke, J. L., & Prados, M. (2009) · Neuro-Oncology · doi:10.1093/neuonc/nop034 · Cited by 49
Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma
Han, S. J., Rolston, J. D., Molinaro, A. M., Clarke, J. L., Prados, M. D., Chang, S., Berger, M. S., DeSilva, A., & Butowski, N. A. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou044 · Cited by 49
Analysis of heterogeneity in T2-weighted MR images can differentiate pseudoprogression from progression in glioblastoma
Booth, T. C., Larkin, T. J., Yuan, Y., Kettunen, M. I., Dawson, S. N., Scoffings, D. J., Canuto, H. C., Vowler, S. L., Kirschenlohr, H. L., Hobson, M., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0176528 · Cited by 49
Dynamic 18F-FET PET is a powerful imaging biomarker in gadolinium-negative gliomas
Kunz, M., Albert, N. L., Unterrainer, M., la Fougère, C. J., Egensperger, R., Schüller, U., Lutz, J., Kreth, S., Tonn, J., Kreth, F.-W., et al. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy098 · Cited by 49
Imaging biomarkers guided anti-angiogenic therapy for malignant gliomas
Kong, Z., Yan, C., Zhu, R., Wang, J., Wang, Y., Wang, Y., Wang, R., Feng, F., & Ma, W. (2018) · NeuroImage Clinical · doi:10.1016/j.nicl.2018.07.001 · Cited by 49
Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma
Kaley, T. J., Panageas, K. S., Pentsova, E. I., Mellinghoff, I. K., Nolan, C. P., Gavrilovic, I. T., DeAngelis, L. M., Abrey, L. E., Holland, E. C., Omuro, A. M. P., et al. (2020) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51009 · Cited by 50
Pseudoprogression versus true progression in glioblastoma patients: A multiapproach literature review. Part 2 – Radiological features and metric markers
Fèvre, C. L., Constans, J., Chambrelant, I., Antoni, D., Bund, C., Leroy‐Freschini, B., Schött, R., Cébula, H., & Noël, G. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103230 · Cited by 50
Etoposide for recurrent spinal cord ependymoma
Chamberlain, M. C. (2002) · Neurology · doi:10.1212/wnl.58.8.1310 · Cited by 49
A Novel Method for Volumetric MRI Response Assessment of Enhancing Brain Tumors
Kanaly, C. W., Ding, D., Mehta, A. I., Waller, A. F., CROCKER, I. R., Desjardins, A., Reardon, D. A., Friedman, A. H., Bigner, D. D., & Sampson, J. H. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016031 · Cited by 49
Assessment of perfusion MRI-derived parameters in evaluating and predicting response to antiangiogenic therapy in patients with newly diagnosed glioblastoma
Essock-Burns, E., Lupo, J., Cha, S., Polley, M.-Y., Butowski, N. A., Chang, S., & Nelson, S. J. (2010) · Neuro-Oncology · doi:10.1093/neuonc/noq143 · Cited by 49
Oxcarbazepine monotherapy in patients with brain tumor-related epilepsy: open-label pilot study for assessing the efficacy, tolerability and impact on quality of life
Maschio, M. C. E., Dinapoli, L., Sperati, F., Fabi, A., Pace, A., Vidiri, A., & Muti, P. C. (2011) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0689-z · Cited by 48
Vandetanib plus sirolimus in adults with recurrent glioblastoma: results of a phase I and dose expansion cohort study
Chheda, M. G., Wen, P. Y., Hochberg, F. H., Chi, A. S., Drappatz, J., Eichler, A. F., Yang, D. X., Beroukhim, R., Norden, A. D., Gerstner, E. R., et al. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-014-1680-2 · Cited by 49
Phospholipid Metabolites in Recurrent Glioblastoma: In Vivo Markers Detect Different Tumor Phenotypes before and under Antiangiogenic Therapy
Hattingen, E., Bähr, O., Rieger, J., Blasel, S., Steinbach, J., & Pilatus, U. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056439 · Cited by 48

Authors: Macdonald, D. R., Cascino, T. L., Schold, S. C., & Cairncross, J. G.
Affiliations: Western University (CA)
ORCID: Cairncross, J G
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 1990-07
Volume: 8
Issue: 7
Pages: 1277-1280
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.1990.8.7.1277
OpenAlex: W1959628099
Cited by: 2,409
References: 11
Citations by year: 2026: 31 · 2025: 21 · 2024: 36 · 2023: 52 · 2022: 53 · 2021: 59 · 2020: 68 · 2019: 75 · 2018: 97 · 2017: 111 · 2016: 125 · 2015: 122 · 2014: 161 · 2013: 186 · 2012: 145
FWCI: 3.90
Type: journal article
Language: en
Open access: closed
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
Keywords: high-grade glioma, supratentorial glioma, response criteria, tumor size measurement, complete response, partial response, stable disease, progressive disease, steroid use, neurologic findings, patient selection, magnetic resonance imaging, computed tomography
MeSH terms: Diagnostic Errors, Drug Evaluation, Glioma, Humans, Magnetic Resonance Imaging, Medical Oncology, Tomography, X-Ray Computed, Supratentorial Neoplasms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Response criteria for phase II studies of supratentorial malignant glioma.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks